PRESENTATION: Rosuvastatin 10mg & 20 mg+Aspirin 75mg+Clopidogrel 75mg 

DRUG CLASS: Antilipemic Agent, HMG-CoA Reductase Inhibitor + non-selective cyclooxygenase (COX) inhibitor+P2Y12 inhibitors  

MECHANISM OF ACTION: Rosuvastatin is an Inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis (reduces the production of mevalonic acid from HMG-CoA); this then results in a compensatory increase in the expression of LDL receptors on hepatocyte membranes 

and a stimulation of LDL catabolism. In addition to the ability of HMG-CoA reductase inhibitors to decrease levels of high-sensitivity C-reactive protein (hsCRP), they also possess pleiotropic properties including improved endothelial function, reduced inflammation at the site of the coronary plaque, inhibition of platelet aggregation, and anticoagulant effects. 

Aspirin (Acetylsalicylic acid - ASA) The inhibition of platelet aggregation by ASA occurs because of its interference with thromboxane A2 in platelets, caused by COX-1 inhibition. Thromboxane A2 is an important lipid responsible for platelet aggregation, which can lead to clot formation and future risk of heart attack or stroke. 

Clopidogrel is metabolized to its active form by carboxylesterase-1. The active form is a platelet inhibitor that irreversibly binds to P2Y12 ADP receptors on platelets. This binding prevents ADP binding to P2Y12 receptors, activation of the glycoprotein GPIIb/IIIa complex, and platelet aggregation. 

INDICATIONS: Treatment or Prevention of heart attack and stroke 

DOSAGE: As Directed by the Physician